home / stock / apls / apls articles

APLS Articles, Apellis Pharmaceuticals Inc. - From 12/11/23

Stock Information
Company Name: Apellis Pharmaceuticals Inc.
Stock Symbol: APLS
Market: NASDAQ
Menu
APLS APLS Quote APLS Short APLS News APLS Articles APLS Message Board
Get APLS Alerts

News, Short Squeeze, Breakout and More Instantly...
Why bluebird bio Shares Are Trading Higher? Here Are Other Stocks Moving In Monday's Mid-Day Session | Benzinga

Shares of bluebird bio, Inc. (NASDAQ: BLUE) rose sharply during Monday’s session after the company presented updated data from its gene thera...
Coinbase, Riot Platforms, Marathon Digital And Other Big Stocks Moving Lower On Monday | Benzinga

U.S. stocks traded mostly mixed, with the Dow Jones index gaining more than 100 points on Monday. Here are some other big stocks recording losses i...

Investigation Alert Apellis Pharmaceuticals, KeyCorp, ACI Worldwide, and Applied Digital: Johnson Fistel, LLP Encourages Long-Term Investors to Submit Their Information Below | Benzinga

SAN DIEGO, Dec. 06, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Johnson Fistel, LLP is investigating potential claims ...

Apellis Pharmaceuticals Upgraded To Buy: Analyst Sees Potential In Syfovre's Strong Launch | Benzinga

BofA Securities analyst Tazeen Ahmad upgraded Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) to Buy from Neutral, raising the pri...
Block To Rally Around 54%? Here Are 10 Top Analyst Forecasts For Tuesday | Benzinga

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgr...

Apellis Pharmaceuticals to Host a Fireside Chat at the 6th Annual Evercore ISI HealthCONx Conference | Benzinga

WALTHAM, Mass., Nov. 21, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (NASDAQ:APLS), today announced that the company will host a fir...

APELLIS ALERT: Bragar Eagel & Squire, P.C. is Investigating Apellis Pharmaceuticals, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm | Benzinga

NEW YORK, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigati...
Apellis Pharmaceuticals Reports Third Quarter 2023 Financial Results | Benzinga

Generated total revenues of $110.4 million in the third quarter, including $75.3 million for SYFOVRE® (pegcetacoplan injection) and $23.9 mi...

Investigation Alert Apellis Pharmaceuticals, KeyCorp, RTX Corporation, and Applied Digital: Johnson Fistel, LLP Encourages Long-Term Investors to Submit Their Information Below | Benzinga

SAN DIEGO, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Johnson Fistel, LLP is investigating potential claims...

Apellis to Present Positive Phase 2 NOBLE Results of Pegcetacoplan in Post-Transplant Recurrence of Primary IC-MPGN and C3G at Kidney Week | Benzinga

In as early as 12 weeks: 80% of patients treated with pegcetacoplan showed a reduction in C3c staining by one or more orders of magnitude of in...
Previous 10 Next 10